Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20074286 | 0.79 | ALDH1A1 (0.46) | TSHRKDM5BALDH1A1KDM4EHPGD | |
| SCHEMBL20074195 | 0.79 | LMNA (0.35) | TSHRKDM5BHPGDLMNAPKM | |
| SCHEMBL2429495 | 0.75 | ENPP1 (0.43) | — | |
| SCHEMBL20075884 | 0.74 | KDM5B (0.35) | TSHRKDM5BALDH1A1KDM4EHPGD | |
| SCHEMBL20074197 | 0.70 | TSHR (0.41) | TSHRKDM5BALDH1A1KDM4EHPGD | |
| SCHEMBL2453480 | 0.69 | MBOAT4 (0.39) | KDM5B | |
| SCHEMBL2422627 | 0.69 | TSHR (0.40) | TSHRALDH1A1TDP1SIRT5 | |
| SCHEMBL11714380 | 0.67 | GAA (0.40) | TSHRALDH1A1KDM4ETDP1SIRT5 | |
| SCHEMBL2464506 | 0.66 | MBOAT4 (0.40) | KDM5B | |
| SCHEMBL20074180 | 0.65 | TSHR (0.45) | TSHRKDM5BALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3525785-B1 | KDM5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-08-27 | — | — | EP | claimed |
| US-10975084-B2 | KDM5 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200048258-A1 | KDM5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | US | disclosed |
| WO-2018071283-A1 | KDM5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048258-A1 | KDM5 INHIBITORS | KDM5A, KDM5B, KDM5C | TSHR 4342/4885KDM5B 2/4885ALDH1A1 1399/4885 |
| US-10975084-B2 | KDM5 inhibitors | KDM5A, KDM5B, KDM5C | TSHR 4342/4885KDM5B 2/4885ALDH1A1 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.